RE:RE:RE:Frustrated ColleaguesNon-sense phase 1a testing 8 healthy subjects could have easily been in motion, not costly. More so would have been set up at recruiting center and on the go, highly reasonable to expect positive results with monoclonal technology like all others that eventually failed in later trials. Bottom line phase 1a really meaning nothing just the beginning of a long process which later resulting are the meaningful. If they did fail safety with these 8 then the company is done.
Need to partner to provide resource infrastructure, spread the risk in running this clinical trial. Acumen is just about 2 years into it and meaningful results will be coming in the 3rd qtr.
Promis has not released the approved protocols, keeping that away from most investors. Can assume like other trials results will be blinded. Folks being told we are going to know right away if it's working have been mislead.
Delay after delay we should know the direction shortly, partner or feed the Boston group again and again, keeping information suppressed. This could be the case Gail has shutdown the social media, they don't have any credible analysts coverage and appear to be controlling and setting the stock price.